首页 > 最新文献

Frontiers in antibiotics最新文献

英文 中文
Antibiotic use in poultry farming: a cross-sectional study of veterinary practices in Tunisia. 家禽养殖中的抗生素使用:突尼斯兽医实践的横断面研究。
Pub Date : 2025-10-14 eCollection Date: 2025-01-01 DOI: 10.3389/frabi.2025.1646766
Mehdi Ben Ali, Badi Chtioui, Hamza Bouchrit, Hatem Laamiri, Hedia Attia El Hili

Antimicrobial resistance (AMR) in poultry production poses a growing public health threat due to the emergence of multidrug-resistant (MDR) bacteria and the risk of transmission to humans through direct or indirect contact with these germs. In Tunisia, limited data on antibiotic use and veterinary prescribing practices hinder the development of effective AMR mitigation strategies, particularly in a sector with high antibiotic consumption. A cross-sectional study was conducted among veterinarian prescribers in avian medicine in Tunisia to assess their antibiotic prescribing behaviours and related practices and to evaluate their potential contribution to AMR emergence and spread. The most frequently reported first and second-line antibiotics were enrofloxacin (20/52 and 14/52), florfenicol (14/52 and 14/52), and doxycycline (7/52 and 6/52). Colistin (10/52) was the most used third-line antibiotic. These antibiotics were often administered without microbiological confirmation. Although 69% had access to accredited labs, 42% relied on rapid antimicrobial susceptibility tests (RASTs). Waste management practices were inadequate, with 50% disposing of biological waste in regular trash and 42% discarding expired antibiotics into the environment. Additionally, 77% reported frequent farmer self-medication. These findings highlight the urgent need for targeted training, improved surveillance, and the application of the One Health approach to tackle AMR in Tunisia's poultry sector.

由于多药耐药细菌的出现以及通过直接或间接接触这些细菌传播给人类的风险,家禽生产中的抗微生物药物耐药性(AMR)构成了日益严重的公共卫生威胁。在突尼斯,关于抗生素使用和兽医处方做法的数据有限,阻碍了制定有效的抗生素耐药性缓解战略,特别是在抗生素消费量高的部门。在突尼斯禽类医学兽医开处方者中开展了一项横断面研究,以评估其抗生素处方行为和相关做法,并评估其对抗生素耐药性出现和传播的潜在影响。报告最多的一线和二线抗生素是恩诺沙星(20/52和14/52)、氟苯尼考(14/52和14/52)和强力霉素(7/52和6/52)。粘菌素(10/52)是使用最多的三线抗生素。这些抗生素通常在没有微生物学证实的情况下使用。虽然69%的人可以获得认可的实验室,但42%的人依赖快速抗菌药物敏感性试验(RASTs)。废物管理做法不充分,50%的生物废物在常规垃圾中处理,42%的人将过期的抗生素丢弃到环境中。此外,77%的人报告说农民经常自我用药。这些发现突出表明迫切需要进行有针对性的培训、改进监测和应用“同一个健康”方法来解决突尼斯家禽业的抗生素耐药性问题。
{"title":"Antibiotic use in poultry farming: a cross-sectional study of veterinary practices in Tunisia.","authors":"Mehdi Ben Ali, Badi Chtioui, Hamza Bouchrit, Hatem Laamiri, Hedia Attia El Hili","doi":"10.3389/frabi.2025.1646766","DOIUrl":"10.3389/frabi.2025.1646766","url":null,"abstract":"<p><p>Antimicrobial resistance (AMR) in poultry production poses a growing public health threat due to the emergence of multidrug-resistant (MDR) bacteria and the risk of transmission to humans through direct or indirect contact with these germs. In Tunisia, limited data on antibiotic use and veterinary prescribing practices hinder the development of effective AMR mitigation strategies, particularly in a sector with high antibiotic consumption. A cross-sectional study was conducted among veterinarian prescribers in avian medicine in Tunisia to assess their antibiotic prescribing behaviours and related practices and to evaluate their potential contribution to AMR emergence and spread. The most frequently reported first and second-line antibiotics were enrofloxacin (20/52 and 14/52), florfenicol (14/52 and 14/52), and doxycycline (7/52 and 6/52). Colistin (10/52) was the most used third-line antibiotic. These antibiotics were often administered without microbiological confirmation. Although 69% had access to accredited labs, 42% relied on rapid antimicrobial susceptibility tests (RASTs). Waste management practices were inadequate, with 50% disposing of biological waste in regular trash and 42% discarding expired antibiotics into the environment. Additionally, 77% reported frequent farmer self-medication. These findings highlight the urgent need for targeted training, improved surveillance, and the application of the One Health approach to tackle AMR in Tunisia's poultry sector.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1646766"},"PeriodicalIF":0.0,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12558877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145402445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Mechanisms and strategies to overcome antibiotic resistance in gastrointestinal pathogens. 社论:克服胃肠道病原体抗生素耐药性的机制和策略。
Pub Date : 2025-10-01 eCollection Date: 2025-01-01 DOI: 10.3389/frabi.2025.1706166
Tales Fernando da Silva, Bartłomiej Grygorcewicz
{"title":"Editorial: Mechanisms and strategies to overcome antibiotic resistance in gastrointestinal pathogens.","authors":"Tales Fernando da Silva, Bartłomiej Grygorcewicz","doi":"10.3389/frabi.2025.1706166","DOIUrl":"10.3389/frabi.2025.1706166","url":null,"abstract":"","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1706166"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12522394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145310135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Demonstration of phage inhibitory action against Clostridium perfringens LMG 11264 within a complex chicken cecal microbiota in vitro. 鸡盲肠菌群中噬菌体对产气荚膜梭菌LMG 11264的体外抑制作用。
Pub Date : 2025-09-18 eCollection Date: 2025-01-01 DOI: 10.3389/frabi.2025.1599939
Maria Wiese, Eline S Klaassens, Volmar Hatt, Angelique Kreikamp, Mirna L Baak, Margreet Heerikhuisen, Jos M B M Van Der Vossen

Introduction: Clostridium perfringens strains may cause foodborne illness, and 95% of human infections are linked to the consumption of contaminated meat, including chicken products. In poultry, C. perfringens infection may cause necrotic enteritis, and infections are associated with high mortality rates partially due to antibiotic resistance, which hampers efficient treatment. In-vitro screening approaches of alternative treatment options, for instance, specific phages, represent a promising strategy for the selection of novel interventions to combat infections.

Material and methods: In this study, we explored the application of a C. perfringens strain LMG 11264-specific phage #7 introduced at 104 pfu/mL to inhibit the growth of C. perfringens at 106 cfu/mL compared to two antibiotics (amoxicillin at 10 µg/mL and clindamycin at 10 µg/mL) within complex chicken cecal microbiota in vitro. Samples for gDNA isolation, qPCR, and metagenome sequencing were taken at the beginning and after 24 and 48 h of incubation.

Results: The C. perfringens strain LMG 11264 proliferated within the untreated complex microbiota and reached levels of approximately 108 and 109 genome equivalents per mL after 24 and 48 h of incubation, respectively. The phage intervention with phage #7 inhibited the growth of C. perfringens LMG 11264 significantly; the inhibitory effects were similar to those exerted by the antibiotic intervention with amoxicillin and stronger than the inhibitory effects with clindamycin. In the absence of the C. perfringens challenge, we found a significant effect of amoxicillin (p = 0.040) or clindamycin (p = 0.000017) compared to the untreated control after 24 h of incubation, and the phage addition did not affect the alpha diversity expressed as Chao index significantly (p = 1). In addition, the endogenous C. perfringens in the chicken microbiota appeared insensitive to phage #7. The phage titer of phage #7 only increased in the presence of the inoculated C. perfringens strain LMG 11264. In conclusion, the i-screen model can be implemented to test the efficacy and specificity of phage therapy in vitro.

导读:产气荚膜梭菌菌株可引起食源性疾病,95%的人类感染与食用受污染的肉类(包括鸡肉产品)有关。在家禽中,产气荚膜原梭菌感染可引起坏死性肠炎,感染与高死亡率有关,部分原因是抗生素耐药性,这妨碍了有效治疗。替代治疗方案的体外筛选方法,例如特异性噬菌体,代表了一种有希望的策略,可以选择新的干预措施来对抗感染。材料和方法:在本研究中,我们探索了产气荚膜荚膜杆菌菌株LMG 11264特异性噬菌体#7在104 pfu/mL的浓度下对产气荚膜荚膜菌生长的抑制作用,并与两种抗生素(阿莫西林10µg/mL和克林霉素10µg/mL)在复杂的鸡盲肠微生物群中的体外抑制作用进行了比较。在孵育开始和孵育24和48 h后分别取样本进行gDNA分离、qPCR和宏基因组测序。结果:产气荚膜荚膜梭菌LMG 11264在未经处理的复杂微生物群中增殖,孵育24小时和48小时后分别达到每mL约108和109个基因组当量的水平。7号噬菌体干预显著抑制产气荚膜梭菌LMG 11264的生长;其抑菌效果与阿莫西林干预抑菌效果相似,强于克林霉素干预抑菌效果。在没有产气弧菌攻毒的情况下,孵育24 h后,我们发现阿莫西林(p = 0.040)或克林霉素(p = 0.000017)对对照的影响显著(p = 0.040),并且噬菌体的添加对表达为Chao指数的α多样性没有显著影响(p = 1)。此外,鸡微生物群中的内源性产气荚膜荚膜原对噬菌体#7不敏感。噬菌体#7的滴度仅在接种了产气荚膜荚膜荚膜菌LMG 11264后升高。综上所述,i-screen模型可用于体外检测噬菌体治疗的疗效和特异性。
{"title":"Demonstration of phage inhibitory action against <i>Clostridium perfringens</i> LMG 11264 within a complex chicken cecal microbiota <i>in vitro</i>.","authors":"Maria Wiese, Eline S Klaassens, Volmar Hatt, Angelique Kreikamp, Mirna L Baak, Margreet Heerikhuisen, Jos M B M Van Der Vossen","doi":"10.3389/frabi.2025.1599939","DOIUrl":"10.3389/frabi.2025.1599939","url":null,"abstract":"<p><strong>Introduction: </strong><i>Clostridium perfringens</i> strains may cause foodborne illness, and 95% of human infections are linked to the consumption of contaminated meat, including chicken products. In poultry, <i>C. perfringens</i> infection may cause necrotic enteritis, and infections are associated with high mortality rates partially due to antibiotic resistance, which hampers efficient treatment. <i>In-vitro</i> screening approaches of alternative treatment options, for instance, specific phages, represent a promising strategy for the selection of novel interventions to combat infections.</p><p><strong>Material and methods: </strong>In this study, we explored the application of a <i>C. perfringens</i> strain LMG 11264-specific phage #7 introduced at 10<sup>4</sup> pfu/mL to inhibit the growth of <i>C. perfringens</i> at 10<sup>6</sup> cfu/mL compared to two antibiotics (amoxicillin at 10 µg/mL and clindamycin at 10 µg/mL) within complex chicken cecal microbiota <i>in vitro.</i> Samples for gDNA isolation, qPCR, and metagenome sequencing were taken at the beginning and after 24 and 48 h of incubation.</p><p><strong>Results: </strong>The <i>C. perfringens</i> strain LMG 11264 proliferated within the untreated complex microbiota and reached levels of approximately 10<sup>8</sup> and 10<sup>9</sup> genome equivalents per mL after 24 and 48 h of incubation, respectively. The phage intervention with phage #7 inhibited the growth of <i>C. perfringens</i> LMG 11264 significantly; the inhibitory effects were similar to those exerted by the antibiotic intervention with amoxicillin and stronger than the inhibitory effects with clindamycin. In the absence of the <i>C. perfringens</i> challenge, we found a significant effect of amoxicillin (<i>p</i> = 0.040) or clindamycin (<i>p</i> = 0.000017) compared to the untreated control after 24 h of incubation, and the phage addition did not affect the alpha diversity expressed as Chao index significantly (<i>p</i> = 1). In addition, the endogenous <i>C. perfringens</i> in the chicken microbiota appeared insensitive to phage #7. The phage titer of phage #7 only increased in the presence of the inoculated <i>C. perfringens</i> strain LMG 11264. In conclusion, the i-screen model can be implemented to test the efficacy and specificity of phage therapy <i>in vitro.</i></p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1599939"},"PeriodicalIF":0.0,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12488702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zoonotic potential of ESBL-producing coliforms in pastorally managed ruminants with subclinical mastitis in Plateau State, Nigeria. 尼日利亚高原州畜牧管理的亚临床乳腺炎反刍动物中产生esbl大肠菌的人畜共患潜力
Pub Date : 2025-09-15 eCollection Date: 2025-01-01 DOI: 10.3389/frabi.2025.1632264
Kenneth Nnamdi Anueyiagu, Ebere Roseann Agusi, Dennis Kabantiyok, Grace Mebi Ayanbimpe, Eugene Ifeanyichukwu Ikeh

Background: Environmental coliform bacteria are frequently the cause of subclinical mastitis (SCM), a serious health issue in the dairy industry. Extended-spectrum β-lactamase (ESBL)-producing coliforms in livestock are a serious public health concern, particularly in environments where people and animals coexist. With an emphasis on their zoonotic and One Health implications, this study sought to evaluate the incidence of SCM and the occurrence of ESBL-producing coliforms in ruminants in Plateau State, Nigeria.

Methods: The California Mastitis Test (CMT) was used to screen 287 milk samples that were taken from cows, ewes, and does. Standard microbiological methods were used to identify the bacterial isolates from CMT-positive samples. The presence of resistance genes (bla TEM and bla CTX-M) was ascertained by PCR, and ESBL production was confirmed phenotypically. Phylogenetic analysis showed genetic diversity and possible horizontal gene transfer among isolates.

Results: Out of 287 milk samples, 79 (27.5%) had subclinical mastitis through the CMT, with a higher prevalence recorded in does 18(22.8%) while ewes and cows recorded 23(29.1%), and 38(48.1%) respectively. Of the 79 CMT-positive samples, the following isolates were identified: Citrobacter freundii (6.3%), Klebsiella pneumoniae (21.6%), K. oxytoca (2.5%), K. aerogenes (6.3%), and E. coli, being the most prevalent in cows (71%). Through PCR, 46 isolates expressed two important ESBL genes, bla TEM and bla CTX-M.

Conclusion: A possible zoonotic reservoir for antibiotic resistance in Nigeria is highlighted by the increased frequency of ESBL-producing coliforms in ruminants with SCM. These results highlight the necessity of implementing integrated One Health initiatives, such as public education, surveillance, and antimicrobial stewardship, in order to reduce the risk of resistant pathogen transmission from animals to people.

背景:环境大肠菌群细菌是亚临床乳腺炎(SCM)的常见病因,是乳制品行业严重的健康问题。牲畜中产生广谱β-内酰胺酶(ESBL)的大肠菌群是一个严重的公共卫生问题,特别是在人与动物共存的环境中。本研究旨在评估尼日利亚高原州反刍动物中SCM的发病率和产生esbl的大肠菌群的发生率,重点关注其人畜共患病和同一健康的影响。方法:采用加州乳腺炎试验(CMT)筛选287份来自奶牛、母羊和公羊的牛奶样本。采用标准微生物学方法对cmt阳性样品中分离的细菌进行鉴定。通过PCR方法确定了抗性基因(bla TEM和bla CTX-M)的存在,并证实了ESBL的产生。系统发育分析显示菌株间存在遗传多样性和水平基因转移。结果:在287份牛奶样本中,79例(27.5%)通过CMT检测发现亚临床乳腺炎,其中18例(22.8%)发病率较高,而母羊和奶牛分别记录了23例(29.1%)和38例(48.1%)。在79份cmt阳性样本中,鉴定出以下分离株:弗氏柠檬酸杆菌(6.3%)、肺炎克雷伯菌(21.6%)、产氧克雷伯菌(2.5%)、产氧克雷伯菌(6.3%)和大肠杆菌(71%),大肠杆菌在奶牛中最常见。通过PCR, 46株分离株表达了两个重要的ESBL基因bla TEM和bla CTX-M。结论:尼日利亚患有SCM的反刍动物中产生esbls大肠菌的频率增加,这可能是抗生素耐药性的人畜共患水库。这些结果突出表明,有必要实施综合的“同一个健康”倡议,如公共教育、监测和抗微生物药物管理,以减少耐药病原体从动物向人传播的风险。
{"title":"Zoonotic potential of ESBL-producing coliforms in pastorally managed ruminants with subclinical mastitis in Plateau State, Nigeria.","authors":"Kenneth Nnamdi Anueyiagu, Ebere Roseann Agusi, Dennis Kabantiyok, Grace Mebi Ayanbimpe, Eugene Ifeanyichukwu Ikeh","doi":"10.3389/frabi.2025.1632264","DOIUrl":"10.3389/frabi.2025.1632264","url":null,"abstract":"<p><strong>Background: </strong>Environmental coliform bacteria are frequently the cause of subclinical mastitis (SCM), a serious health issue in the dairy industry. Extended-spectrum β-lactamase (ESBL)-producing coliforms in livestock are a serious public health concern, particularly in environments where people and animals coexist. With an emphasis on their zoonotic and One Health implications, this study sought to evaluate the incidence of SCM and the occurrence of ESBL-producing coliforms in ruminants in Plateau State, Nigeria.</p><p><strong>Methods: </strong>The California Mastitis Test (CMT) was used to screen 287 milk samples that were taken from cows, ewes, and does. Standard microbiological methods were used to identify the bacterial isolates from CMT-positive samples. The presence of resistance genes (<i>bla</i> <sub>TEM</sub> and <i>bla</i> <sub>CTX-M</sub>) was ascertained by PCR, and ESBL production was confirmed phenotypically. Phylogenetic analysis showed genetic diversity and possible horizontal gene transfer among isolates.</p><p><strong>Results: </strong>Out of 287 milk samples, 79 (27.5%) had subclinical mastitis through the CMT, with a higher prevalence recorded in does 18(22.8%) while ewes and cows recorded 23(29.1%), and 38(48.1%) respectively. Of the 79 CMT-positive samples, the following isolates were identified: <i>Citrobacter freundii</i> (6.3%), <i>Klebsiella pneumoniae</i> (21.6%), <i>K. oxytoca</i> (2.5%), <i>K. aerogenes</i> (6.3%), and <i>E. coli</i>, being the most prevalent in cows (71%). Through PCR, 46 isolates expressed two important ESBL genes, <i>bla</i> <sub>TEM</sub> and <i>bla</i> <sub>CTX-M.</sub></p><p><strong>Conclusion: </strong>A possible zoonotic reservoir for antibiotic resistance in Nigeria is highlighted by the increased frequency of ESBL-producing coliforms in ruminants with SCM. These results highlight the necessity of implementing integrated One Health initiatives, such as public education, surveillance, and antimicrobial stewardship, in order to reduce the risk of resistant pathogen transmission from animals to people.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1632264"},"PeriodicalIF":0.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An evaluation of antibiotic options for the treatment of biothreat pathogens. 评估治疗生物威胁病原体的抗生素选择。
Pub Date : 2025-08-14 eCollection Date: 2025-01-01 DOI: 10.3389/frabi.2025.1611588
J Matthew Meinig, Michelle Nelson, Christopher K Cote, Stevan R Emmett, Sarah V Harding

The development of medical countermeasures against pathogens of biodefense concern remains critical to protecting military and public health. This review compares data detailing antibacterial activity and efficacy for a selection of antibiotics evaluated against potential bacterial biothreat pathogens. The human safety and tolerability of these formulations were also considered. This review includes finafloxacin, levofloxacin, delafloxacin, omadacycline, gepotidacin, tebipenem and sulopenem. The selection criteria of these antibiotics were 1) the availability of an oral formulation, 2) the regulatory status (licensed by a regulatory authority or in an advanced stage of development) and 3) the availability of publicly available information on the biodefence pathogens of concern. We hope to highlight approved or advanced clinical candidates that have significant and unique potential in the biodefense space which may be deployed to protect both the public and warfighter against these bacterial infections.

发展针对生物防御关注病原体的医疗对策对于保护军队和公众健康仍然至关重要。这篇综述比较了数据详细抗菌活性和功效的选择抗生素评估对潜在的细菌生物威胁病原体。还考虑了这些制剂的人体安全性和耐受性。本文综述了非那沙星、左氧氟沙星、德拉沙星、奥马达环素、吉波替达星、替比培南和舒洛培南。这些抗生素的选择标准是1)口服制剂的可用性,2)监管状态(获得监管机构许可或处于开发的后期阶段)和3)有关关注的生物防御病原体的公开信息的可用性。我们希望突出在生物防御领域具有重要和独特潜力的已批准或先进的临床候选药物,这些候选药物可以用于保护公众和作战人员免受这些细菌感染。
{"title":"An evaluation of antibiotic options for the treatment of biothreat pathogens.","authors":"J Matthew Meinig, Michelle Nelson, Christopher K Cote, Stevan R Emmett, Sarah V Harding","doi":"10.3389/frabi.2025.1611588","DOIUrl":"10.3389/frabi.2025.1611588","url":null,"abstract":"<p><p>The development of medical countermeasures against pathogens of biodefense concern remains critical to protecting military and public health. This review compares data detailing antibacterial activity and efficacy for a selection of antibiotics evaluated against potential bacterial biothreat pathogens. The human safety and tolerability of these formulations were also considered. This review includes finafloxacin, levofloxacin, delafloxacin, omadacycline, gepotidacin, tebipenem and sulopenem. The selection criteria of these antibiotics were 1) the availability of an oral formulation, 2) the regulatory status (licensed by a regulatory authority or in an advanced stage of development) and 3) the availability of publicly available information on the biodefence pathogens of concern. We hope to highlight approved or advanced clinical candidates that have significant and unique potential in the biodefense space which may be deployed to protect both the public and warfighter against these bacterial infections.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1611588"},"PeriodicalIF":0.0,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12392784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of antibiotic utilization patterns in an Indian Level-1 Trauma Center: a pilot study exploring days of antibiotic spectrum coverage and defined daily doses using WHO AWaRe classification trends. 评估印度一级创伤中心的抗生素使用模式:一项利用世卫组织AWaRe分类趋势探索抗生素谱覆盖天数和确定日剂量的试点研究。
Pub Date : 2025-07-15 eCollection Date: 2025-01-01 DOI: 10.3389/frabi.2025.1578217
M Nizam Ahmed, Arpan Kumar Thakur, Smriti Srivastava, Aparna Ningombam, Madhavi Kirti, Sushma Sagar, Keshav Goyal, Subodh Kumar, Ashish Bindra, Gyaninder Pal Singh, Navdeep Sokhal, Richa Aggarwal, Vijay Sharma, Samarth Mittal, Kamran Farooque, Purva Mathur

Background: Rising antimicrobial resistance (AMR) necessitates innovative metrics, such as days of antibiotic spectrum coverage (DASC), to optimize antibiotic stewardship. This study evaluated antibiotic use in an Indian trauma center using DASC, defined daily doses (DDD), and the World Health Organization (WHO) Access, Watch, Reserve (AWaRe) classification.

Methods: This retrospective cohort study analyzed data from 1,812 adult inpatients (mean age: 35 years; 70% male; 80% with polytrauma) admitted to a 250-bed Level-1 Trauma Center at the All India Institute of Medical Sciences (AIIMS), India, from August to October 2022. We measured days of therapy (DOT), DDD, and DASC for 46 antibiotics across 12 pathogens [e.g., methicillin-susceptible Staphylococcus aureus (MSSA), carbapenem-resistant Enterobacteriaceae]. DASC scores were developed through expert consensus and local antibiogram data, and validated using Pearson's correlation with DOT (R = 0.43, p < 0.1) and DDD (R = 0.21). Differences in antibiotic usage between the ICU and ward were analyzed using a t-test in R software.

Results: Total antibiotic consumption was 81,064.6 g (3,142 DDD/1,000 patient-days). The Watch group antibiotics dominated usage (37%, 16,018.6 g), resulting in a low Access-to-Watch ratio (0.47). ICU settings showed higher DDD values (326 vs. 193/1,000 patient-days, p < 0.05) and DASC/DOT ratios (mean: 3; 95% CI: 2.73-4.01). Piperacillin-tazobactam accounted for the largest share of the Watch category use (5,952.9 g). DASC values (mean 4401.5, 95% CI: 3592-5211.1) showed a moderate correlation with DOT (R = 0.43, p < 0.1), offering spectrum-specific insights.

Conclusions: Excessive use of the Watch group antibiotics contributes significantly to AMR. However, DASC's novel, spectrum-focused approach offers a transformative tool for antibiotic stewardship, supporting targeted de-escalation and improved benchmarking. These findings underscore the urgent need for policy reforms to enforce adherence to the WHO AWaRe classification in Indian centers, potentially reducing AMR-related mortality (30% higher with resistant infections). Integrating DASC into global Antimicrobial stewardship (AMS) programs may redefine antibiotic prescribing practices and help mitigate the AMR crisis.

背景:不断上升的抗菌素耐药性(AMR)需要创新指标,如抗生素谱覆盖天数(DASC),以优化抗生素管理。本研究使用DASC、限定日剂量(DDD)和世界卫生组织(WHO)获取、观察、储备(AWaRe)分类评估了印度创伤中心的抗生素使用情况。方法:本回顾性队列研究分析了1812例成人住院患者(平均年龄:35岁;男性70%;2022年8月至10月,在印度全印度医学科学研究所(AIIMS)拥有250张床位的一级创伤中心住院。我们测量了12种病原体中46种抗生素的治疗天数(DOT)、DDD和DASC[例如,甲氧西林敏感金黄色葡萄球菌(MSSA)、碳青霉烯耐药肠杆菌科]。通过专家共识和当地抗生素谱数据制定DASC评分,并使用Pearson与DOT (R = 0.43, p < 0.1)和DDD (R = 0.21)的相关性进行验证。ICU与病房抗生素使用差异采用R软件t检验分析。结果:总抗生素用量为81,064.6 g (3,142 DDD/1,000患者日)。Watch组抗生素的使用占主导地位(37%,16018.6 g),导致获得Watch的比率较低(0.47)。ICU设置的DDD值较高(326 vs. 193/ 1000患者-天,p < 0.05), DASC/DOT比值较高(平均值:3;95% ci: 2.73-4.01)。哌拉西林-他唑巴坦占Watch类药物使用量的最大份额(5,952.9 g)。DASC值(平均值4401.5,95% CI: 3592-5211.1)显示与DOT中度相关(R = 0.43, p < 0.1),提供光谱特异性见解。结论:过量使用Watch组抗生素是导致AMR的重要因素。然而,DASC新颖的、以频谱为重点的方法为抗生素管理提供了一种变革性的工具,支持有针对性的降级和改进的基准。这些发现强调迫切需要进行政策改革,以在印度各中心强制执行世卫组织AWaRe分类,从而有可能降低与抗菌素耐药性相关的死亡率(耐药感染高出30%)。将DASC纳入全球抗菌素管理(AMS)计划可能会重新定义抗生素处方做法,并有助于缓解抗菌素耐药性危机。
{"title":"Assessment of antibiotic utilization patterns in an Indian Level-1 Trauma Center: a pilot study exploring days of antibiotic spectrum coverage and defined daily doses using WHO AWaRe classification trends.","authors":"M Nizam Ahmed, Arpan Kumar Thakur, Smriti Srivastava, Aparna Ningombam, Madhavi Kirti, Sushma Sagar, Keshav Goyal, Subodh Kumar, Ashish Bindra, Gyaninder Pal Singh, Navdeep Sokhal, Richa Aggarwal, Vijay Sharma, Samarth Mittal, Kamran Farooque, Purva Mathur","doi":"10.3389/frabi.2025.1578217","DOIUrl":"10.3389/frabi.2025.1578217","url":null,"abstract":"<p><strong>Background: </strong>Rising antimicrobial resistance (AMR) necessitates innovative metrics, such as days of antibiotic spectrum coverage (DASC), to optimize antibiotic stewardship. This study evaluated antibiotic use in an Indian trauma center using DASC, defined daily doses (DDD), and the World Health Organization (WHO) Access, Watch, Reserve (AWaRe) classification.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed data from 1,812 adult inpatients (mean age: 35 years; 70% male; 80% with polytrauma) admitted to a 250-bed Level-1 Trauma Center at the All India Institute of Medical Sciences (AIIMS), India, from August to October 2022. We measured days of therapy (DOT), DDD, and DASC for 46 antibiotics across 12 pathogens [e.g., methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA), carbapenem-resistant <i>Enterobacteriaceae</i>]. DASC scores were developed through expert consensus and local antibiogram data, and validated using Pearson's correlation with DOT (R = 0.43, p < 0.1) and DDD (R = 0.21). Differences in antibiotic usage between the ICU and ward were analyzed using a t-test in R software.</p><p><strong>Results: </strong>Total antibiotic consumption was 81,064.6 g (3,142 DDD/1,000 patient-days). The Watch group antibiotics dominated usage (37%, 16,018.6 g), resulting in a low Access-to-Watch ratio (0.47). ICU settings showed higher DDD values (326 vs. 193/1,000 patient-days, p < 0.05) and DASC/DOT ratios (mean: 3; 95% CI: 2.73-4.01). Piperacillin-tazobactam accounted for the largest share of the Watch category use (5,952.9 g). DASC values (mean 4401.5, 95% CI: 3592-5211.1) showed a moderate correlation with DOT (R = 0.43, p < 0.1), offering spectrum-specific insights.</p><p><strong>Conclusions: </strong>Excessive use of the Watch group antibiotics contributes significantly to AMR. However, DASC's novel, spectrum-focused approach offers a transformative tool for antibiotic stewardship, supporting targeted de-escalation and improved benchmarking. These findings underscore the urgent need for policy reforms to enforce adherence to the WHO AWaRe classification in Indian centers, potentially reducing AMR-related mortality (30% higher with resistant infections). Integrating DASC into global Antimicrobial stewardship (AMS) programs may redefine antibiotic prescribing practices and help mitigate the AMR crisis.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1578217"},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
National antibiotic consumption for human use in Chad (2017-2021): a descriptive cross-sectional study. 乍得人用抗生素全国消费量(2017-2021年):一项描述性横断面研究。
Pub Date : 2025-07-11 eCollection Date: 2025-01-01 DOI: 10.3389/frabi.2025.1612557
Zongo R Frank Edgard, Kadidjia Bakari Traoré, Colette Ngabéré, Martine Yoyammel, Abatcha Oumar Kadai, John Eyong Efobi, Mathieu Hota, Didi Lamireou, Badawi Haroun Mahamat, Hamit Mahamat Alio, Jacques L Tamuzi, Patrick D M C Katoto, Charles S Wiysonge, Blanche-Philomene Melanga Anya

Background: Antibiotic resistance (ABR) to commonly used antibiotics is significant in sub-Saharan Africa (SSA). In SSA, Chad has one of the highest antimicrobial resistance (AMR) rates. The link between ABR and antibiotic consumption (ABC) is well-established. However, no ABC-related studies have been conducted in Chad recently. The purpose of this study is to examine the trajectory of ABC in Chad from 2017 to 2021, using the World Health Organization's (WHO) Access, Watch, and Reserve (AWaRe) antibiotic classification.

Methods: A descriptive retrospective study was conducted in N'Djamena, using antibiotic import and distribution data collected from the General Directorate of Pharmacy and four wholesale distributors of medicines. The defined daily doses (DDDs) and the mean relative change (MRC) were used to compute the results. Results were presented in terms of tables and graphs. The results were compared to the WHO's guidelines for ABC use via the AWaRe categorization.

Results: Between 2017 and 2021, an average ABC of 2.5 doses per inhabitant per year was observed, peaking in 2020 at 5.3 doses per inhabitant. In terms of DDD, the ten most commonly consumed antibiotics during the time, in descending order, were amoxicillin, ampicillin, sulfamethoxazole/trimethoprim, doxycycline, ciprofloxacin, phenoxymethyl-penicillin, erythromycin, ceftriaxone, azithromycin, and gentamicin. However, the MRC analysis detected an increase in benzathine benzyl penicillin, benzylpenicillin, ampicillin, amoxicillin+clavulanic acid, flucloxacillin, ceftriaxone, cefixime, cefpodoxime and cefalexin, cotrimoxazole, ciprofloxacin, levofloxacin, norfloxacin, ofloxacin, and azithromycin. Controversially, amoxicillin, cefotaxime, doxycycline, erythromycin, and moxifloxacin had a lower MRC from 2017 to 2021. Although 90% of the ABC are from the "Access" group, the "Watch" group has increased over time.

Conclusions: Our findings indicated a significant ABC in the Chadian population from 2017 to 2021, which may elucidate the country's elevated ABR. On average, 90% of ABC were categorized in the "Access" group, although utilization of the Watch group increased over time. This requires the prompt implementation of the monitoring system for ABC at all tiers in Chad.

背景:在撒哈拉以南非洲(SSA),对常用抗生素的耐药性(ABR)很重要。在撒哈拉以南非洲,乍得是抗菌素耐药性(AMR)最高的国家之一。ABR与抗生素消费(ABC)之间的联系已得到证实。但是,最近在乍得没有进行与abc有关的研究。本研究的目的是利用世界卫生组织(WHO)的获取、观察和储备(AWaRe)抗生素分类,研究2017年至2021年乍得ABC的发展轨迹。方法:在恩贾梅纳进行了一项描述性回顾性研究,使用从药学总局和四家药品批发经销商收集的抗生素进口和分销数据。用限定日剂量(DDDs)和平均相对变化(MRC)计算结果。结果以表格和图表的形式呈现。通过AWaRe分类,将结果与世界卫生组织的ABC使用指南进行比较。结果:在2017年至2021年期间,观察到的平均ABC为每位居民每年2.5剂,到2020年达到峰值,为每位居民5.3剂。在DDD方面,10种最常使用的抗生素,从大到小依次是阿莫西林、氨苄西林、磺胺甲恶唑/甲氧苄啶、多西环素、环丙沙星、苯氧甲基青霉素、红霉素、头孢曲松、阿奇霉素和庆大霉素。然而,MRC分析检测到苄星青霉素、苄青霉素、氨苄西林、阿莫西林+克拉维酸、氟氯西林、头孢曲松、头孢克肟、头孢多肟和头孢alexin、复方新诺明、环丙沙星、左氧氟沙星、诺氟沙星、氧氟沙星和阿奇霉素的含量增加。有争议的是,从2017年到2021年,阿莫西林、头孢噻肟、多西环素、红霉素和莫西沙星的MRC较低。虽然90%的ABC来自“访问”组,但“观察”组随着时间的推移而增加。结论:我们的研究结果表明,从2017年到2021年,乍得人口中的ABC显著增加,这可能解释了该国ABR升高的原因。平均而言,90%的ABC被归类为“访问”组,尽管观察组的利用率随着时间的推移而增加。这就要求在乍得各级迅速实施ABC监测系统。
{"title":"National antibiotic consumption for human use in Chad (2017-2021): a descriptive cross-sectional study.","authors":"Zongo R Frank Edgard, Kadidjia Bakari Traoré, Colette Ngabéré, Martine Yoyammel, Abatcha Oumar Kadai, John Eyong Efobi, Mathieu Hota, Didi Lamireou, Badawi Haroun Mahamat, Hamit Mahamat Alio, Jacques L Tamuzi, Patrick D M C Katoto, Charles S Wiysonge, Blanche-Philomene Melanga Anya","doi":"10.3389/frabi.2025.1612557","DOIUrl":"10.3389/frabi.2025.1612557","url":null,"abstract":"<p><strong>Background: </strong>Antibiotic resistance (ABR) to commonly used antibiotics is significant in sub-Saharan Africa (SSA). In SSA, Chad has one of the highest antimicrobial resistance (AMR) rates. The link between ABR and antibiotic consumption (ABC) is well-established. However, no ABC-related studies have been conducted in Chad recently. The purpose of this study is to examine the trajectory of ABC in Chad from 2017 to 2021, using the World Health Organization's (WHO) Access, Watch, and Reserve (AWaRe) antibiotic classification.</p><p><strong>Methods: </strong>A descriptive retrospective study was conducted in N'Djamena, using antibiotic import and distribution data collected from the General Directorate of Pharmacy and four wholesale distributors of medicines. The defined daily doses (DDDs) and the mean relative change (MRC) were used to compute the results. Results were presented in terms of tables and graphs. The results were compared to the WHO's guidelines for ABC use via the AWaRe categorization.</p><p><strong>Results: </strong>Between 2017 and 2021, an average ABC of 2.5 doses per inhabitant per year was observed, peaking in 2020 at 5.3 doses per inhabitant. In terms of DDD, the ten most commonly consumed antibiotics during the time, in descending order, were amoxicillin, ampicillin, sulfamethoxazole/trimethoprim, doxycycline, ciprofloxacin, phenoxymethyl-penicillin, erythromycin, ceftriaxone, azithromycin, and gentamicin. However, the MRC analysis detected an increase in benzathine benzyl penicillin, benzylpenicillin, ampicillin, amoxicillin+clavulanic acid, flucloxacillin, ceftriaxone, cefixime, cefpodoxime and cefalexin, cotrimoxazole, ciprofloxacin, levofloxacin, norfloxacin, ofloxacin, and azithromycin. Controversially, amoxicillin, cefotaxime, doxycycline, erythromycin, and moxifloxacin had a lower MRC from 2017 to 2021. Although 90% of the ABC are from the \"Access\" group, the \"Watch\" group has increased over time.</p><p><strong>Conclusions: </strong>Our findings indicated a significant ABC in the Chadian population from 2017 to 2021, which may elucidate the country's elevated ABR. On average, 90% of ABC were categorized in the \"Access\" group, although utilization of the Watch group increased over time. This requires the prompt implementation of the monitoring system for ABC at all tiers in Chad.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1612557"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Temporal dynamics of antimicrobial resistance gene abundances in chicken manure and anaerobic digestate. 鸡粪和厌氧消化液中抗微生物基因丰度的时间动态。
Pub Date : 2025-06-27 eCollection Date: 2025-01-01 DOI: 10.3389/frabi.2025.1612886
Aleksandra Atanasova, Thomas Amon, Uwe Roesler, Anika Friese, Roswitha Merle, Tina Kabelitz

Introduction: Antimicrobial resistance (AMR) can spread in microorganisms through the transfer of antimicrobial resistance genes (ARGs). Livestock husbandry is one of the pathways for AMR emergence and transmission. Chicken manure contains valuable nutrients for agricultural field fertilization and can be used as input material for biogas production by anaerobic digestion (AD). However, usually, chicken manure also contains quite high levels of ARGs. In this study, we investigated the presence and temporal dynamics of ARGs against different antibiotic classes in chicken manure and anaerobic digestate as a source of AMR spread.

Methods: To get an overview of the ARG profiles, we quantified the abundances of 374 ARGs by high-throughput (HT)-PCR. We studied eight selected ARGs (tetA, tetX, sul1, sul2, lnuF, emrD, aadA, and tnpA) using qPCR in chicken manure from different flocks and animal ages and in digestate from different AD time points.

Results: Chicken manure showed higher amounts of ARGs compared to digestate, which was characterized by a higher ARG diversity. We observed that the effect of chicken age differed between the flocks. ARG abundances in digestate from different time points and different treatment conditions did not exhibit major changes.

Conclusion: The flocks' variability had no relevant effect on ARG abundances in chicken manure, likely due to similar growth conditions. However, manure ARG content increased with the age of the chickens. In our experimental batch setup, AD was more effective in reducing AMR microorganisms than reducing ARGs. Further investigations on process optimization or the application of pre-treatment methods could enhance ARG reduction. Notably, pre-mixing chicken manure with material from a biogas plant prior to processing resulted in a lower ARG load compared to untreated chicken manure.

抗菌素耐药性(AMR)可以通过抗菌素耐药基因(ARGs)的转移在微生物中传播。畜牧业是AMR出现和传播的途径之一。鸡粪含有对农田施肥有价值的营养物质,可以作为厌氧消化(AD)生产沼气的投入材料。然而,通常情况下,鸡粪也含有相当高水平的arg。在这项研究中,我们研究了鸡粪和厌氧消化液中ARGs对不同抗生素类别的存在和时间动态,作为AMR传播的来源。方法:采用高通量(HT)-PCR方法对374个ARG的丰度进行定量分析。我们利用qPCR技术研究了不同鸡群、不同动物年龄的鸡粪和不同AD时间点的消化液中筛选出的8种ARGs (tetA、tetX、sul1、sul2、lnuF、emrD、aadA和tnpA)。结果:鸡粪中ARG含量高于消化液,其特点是ARG多样性更高。我们观察到鸡龄的影响在不同的鸡群之间是不同的。不同时间点、不同处理条件下消化液中ARG丰度变化不大。结论:鸡群的变异对鸡粪中ARG丰度没有相关影响,可能是由于相似的生长条件。然而,随着鸡龄的增加,粪便中ARG含量逐渐增加。在我们的实验批量设置中,AD在减少AMR微生物方面比减少ARGs更有效。进一步研究工艺优化或前处理方法的应用可以提高ARG的减少。值得注意的是,与未经处理的鸡粪相比,在处理前将鸡粪与沼气厂的材料预混合可产生更低的ARG负荷。
{"title":"Temporal dynamics of antimicrobial resistance gene abundances in chicken manure and anaerobic digestate.","authors":"Aleksandra Atanasova, Thomas Amon, Uwe Roesler, Anika Friese, Roswitha Merle, Tina Kabelitz","doi":"10.3389/frabi.2025.1612886","DOIUrl":"10.3389/frabi.2025.1612886","url":null,"abstract":"<p><strong>Introduction: </strong>Antimicrobial resistance (AMR) can spread in microorganisms through the transfer of antimicrobial resistance genes (ARGs). Livestock husbandry is one of the pathways for AMR emergence and transmission. Chicken manure contains valuable nutrients for agricultural field fertilization and can be used as input material for biogas production by anaerobic digestion (AD). However, usually, chicken manure also contains quite high levels of ARGs. In this study, we investigated the presence and temporal dynamics of ARGs against different antibiotic classes in chicken manure and anaerobic digestate as a source of AMR spread.</p><p><strong>Methods: </strong>To get an overview of the ARG profiles, we quantified the abundances of 374 ARGs by high-throughput (HT)-PCR. We studied eight selected ARGs (<i>tetA</i>, <i>tetX</i>, <i>sul1</i>, <i>sul2</i>, <i>lnuF</i>, <i>emrD</i>, <i>aadA</i>, and <i>tnpA</i>) using qPCR in chicken manure from different flocks and animal ages and in digestate from different AD time points.</p><p><strong>Results: </strong>Chicken manure showed higher amounts of ARGs compared to digestate, which was characterized by a higher ARG diversity. We observed that the effect of chicken age differed between the flocks. ARG abundances in digestate from different time points and different treatment conditions did not exhibit major changes.</p><p><strong>Conclusion: </strong>The flocks' variability had no relevant effect on ARG abundances in chicken manure, likely due to similar growth conditions. However, manure ARG content increased with the age of the chickens. In our experimental batch setup, AD was more effective in reducing AMR microorganisms than reducing ARGs. Further investigations on process optimization or the application of pre-treatment methods could enhance ARG reduction. Notably, pre-mixing chicken manure with material from a biogas plant prior to processing resulted in a lower ARG load compared to untreated chicken manure.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1612886"},"PeriodicalIF":0.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12245806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synergistic effects of Pandanus fascicularis extracts and azithromycin: in vitro and in silico antimicrobial investigation against MDR clinical strains. 束状豆提取物与阿奇霉素协同作用:体外和室内对耐多药临床菌株的抗菌研究。
Pub Date : 2025-05-29 eCollection Date: 2025-01-01 DOI: 10.3389/frabi.2025.1552382
Mst Hajera Khatun, Md Rashedul Islam, Shikha Khatun, Amro Ahmed Zalah, Md Hadisur Rahman Rony, Mst Munira Khatun, Emad Essa A Wasili, Jaytirmoy Barmon, Saad Ahmed Sami, Abdulrahman Hadi Masmali, Ishtiaq Qadri

Background: Antibiotic-resistant bacteria are becoming a significant global concern. To combat the spread of resistance or reverse multidrug resistance, developing novel antimicrobials and/or resistance modulators is essential. This study aimed to evaluate the synergistic effects of the methanolic extract of Pandanus fascicularis fruits (MEPFF) in combination with azithromycin against multidrug-resistant bacteria.

Methods: Phytochemical analysis along with the determination of total phenolic content (TPC), total flavonoid content (TFC), and total antioxidant capacity (TAC) of MEPFF, was performed using standard procedure. The extract's DPPH free radical scavenging activity was assessed to evaluate its potential antioxidant activity. The minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of MEPFF against Staphylococcus aureus, Bacillus cereus, Escherichia coli, and Pseudomonas aeruginosa were determined, followed by an analysis of the synergistic effect with azithromycin, as well as the activity of azithromycin alone. Subsequently, the drug-likeness, antibacterial activity, and toxicological properties were analyzed using in silico tools.

Results: The quantitative investigation found terpenoids, flavonoids, tannins, phenolics, saponins, cardiac glycosides, and alkaloids in MEPFF. The TFC, TPC, and TAC of MEPFF were found at 183 ± 9.54 mg QE, 248.33 ± 11.06 mg GAE, and 95.33 ± 8.33 mg AAE/gm extract. The extract showed significant antioxidant activity in the DPPH experiment, with an IC50 value of 12.13±0.53 µg/ml. Azithromycin and the extract together have far greater antibacterial action against all four bacterial strains. The minimal inhibitory concentration (MIC) is 3.67 ± 1.15 to 5.83 ± 0.76 mg/mL, while the minimum bactericidal concentration (MBC) is 4.33 ± 1.26 to 7.33 ± 1.04 mg/mL. In silico studies revealed that pandamarilactone-1, nonpandamarilactone-B, and thiamine had the best docking energy (-9.9, -8.9, and -8.5 kcal/mol), suggesting most active compounds against MPh-II protein.

Conclusion: The extract enhances antibiotic therapy and suggests that the aforesaid synergistic drug-herb combinations may treat MDR bacterial infections.

背景:抗生素耐药细菌正成为全球关注的一个重大问题。为了遏制耐药性的传播或逆转多药耐药性,开发新的抗微生物药物和/或耐药性调节剂至关重要。本研究旨在研究束状熊猫果甲醇提取物(MEPFF)与阿奇霉素联用对多重耐药菌的协同作用。方法:采用标准方法进行植物化学分析,并测定其总酚含量(TPC)、总黄酮含量(TFC)和总抗氧化能力(TAC)。通过测定提取物对DPPH自由基的清除活性来评价其潜在的抗氧化活性。测定了MEPFF对金黄色葡萄球菌、蜡样芽孢杆菌、大肠杆菌和铜绿假单胞菌的最小抑菌浓度(MIC)和最小杀菌浓度(MBC),并分析了其与阿奇霉素的协同作用以及与阿奇霉素单独作用的活性。随后,使用硅工具分析了药物相似性,抗菌活性和毒理学特性。结果:通过定量分析,发现了黄酮类、萜类、单宁类、酚类、皂苷类、心苷类和生物碱类化合物。MEPFF在QE(183±9.54 mg)、GAE(248.33±11.06 mg)和AAE(95.33±8.33 mg /gm)时的TFC、TPC和TAC分别为:在DPPH实验中,该提取物显示出显著的抗氧化活性,IC50值为12.13±0.53µg/ml。阿奇霉素和提取物一起对所有四种细菌菌株都有更大的抗菌作用。最小抑菌浓度(MIC)为3.67±1.15 ~ 5.83±0.76 mg/mL,最小杀菌浓度(MBC)为4.33±1.26 ~ 7.33±1.04 mg/mL。结果表明,熊猫酰胺内酯-1、非熊猫酰胺内酯- b和硫胺素具有最佳的对接能量(-9.9、-8.9和-8.5 kcal/mol),表明它们是抗MPh-II蛋白活性最强的化合物。结论:该提取物对抗生素治疗有增强作用,提示上述协同药-草联合治疗耐多药细菌感染具有一定的疗效。
{"title":"Synergistic effects of <i>Pandanus fascicularis</i> extracts and azithromycin: <i>in vitro</i> and <i>in silico</i> antimicrobial investigation against MDR clinical strains.","authors":"Mst Hajera Khatun, Md Rashedul Islam, Shikha Khatun, Amro Ahmed Zalah, Md Hadisur Rahman Rony, Mst Munira Khatun, Emad Essa A Wasili, Jaytirmoy Barmon, Saad Ahmed Sami, Abdulrahman Hadi Masmali, Ishtiaq Qadri","doi":"10.3389/frabi.2025.1552382","DOIUrl":"10.3389/frabi.2025.1552382","url":null,"abstract":"<p><strong>Background: </strong>Antibiotic-resistant bacteria are becoming a significant global concern. To combat the spread of resistance or reverse multidrug resistance, developing novel antimicrobials and/or resistance modulators is essential. This study aimed to evaluate the synergistic effects of the methanolic extract of <i>Pandanus fascicularis</i> fruits (MEPFF) in combination with azithromycin against multidrug-resistant bacteria.</p><p><strong>Methods: </strong>Phytochemical analysis along with the determination of total phenolic content (TPC), total flavonoid content (TFC), and total antioxidant capacity (TAC) of MEPFF, was performed using standard procedure. The extract's DPPH free radical scavenging activity was assessed to evaluate its potential antioxidant activity. The minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of MEPFF against <i>Staphylococcus aureus</i>, <i>Bacillus cereus</i>, <i>Escherichia coli</i>, and <i>Pseudomonas aeruginosa</i> were determined, followed by an analysis of the synergistic effect with azithromycin, as well as the activity of azithromycin alone. Subsequently, the drug-likeness, antibacterial activity, and toxicological properties were analyzed using in silico tools.</p><p><strong>Results: </strong>The quantitative investigation found terpenoids, flavonoids, tannins, phenolics, saponins, cardiac glycosides, and alkaloids in MEPFF. The TFC, TPC, and TAC of MEPFF were found at 183 ± 9.54 mg QE, 248.33 ± 11.06 mg GAE, and 95.33 ± 8.33 mg AAE/gm extract. The extract showed significant antioxidant activity in the DPPH experiment, with an IC50 value of 12.13±0.53 µg/ml. Azithromycin and the extract together have far greater antibacterial action against all four bacterial strains. The minimal inhibitory concentration (MIC) is 3.67 ± 1.15 to 5.83 ± 0.76 mg/mL, while the minimum bactericidal concentration (MBC) is 4.33 ± 1.26 to 7.33 ± 1.04 mg/mL. In silico studies revealed that pandamarilactone-1, nonpandamarilactone-B, and thiamine had the best docking energy (-9.9, -8.9, and -8.5 kcal/mol), suggesting most active compounds against MPh-II protein.</p><p><strong>Conclusion: </strong>The extract enhances antibiotic therapy and suggests that the aforesaid synergistic drug-herb combinations may treat MDR bacterial infections.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1552382"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12159755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials. 在结核病药物试验中纳入以患者为中心的非微生物终点和生物标志物。
Pub Date : 2025-05-22 eCollection Date: 2025-01-01 DOI: 10.3389/frabi.2025.1570989
Andrew R DiNardo, Wilbert Sabiiti, Stephen H Gillespie, Sophia B Georghiou, Norbert Heinrich, Norbert Hittel, Sami Taghlabi, Danna Carrero Longlax, Mikashmi Kohli, Ursula Panzner, Collins Musia, Christoph Lange, Anca Vasiliu, Rob J W Arts, Anna M Mandalakas, Morten Ruhwald, Lieven J Stuyver, Reinout van Crevel

Tuberculosis drug trials are primarily designed to identify antibiotic regimens with the strongest potency to kill Mycobacterium tuberculosis. However, microbiologic cure is not synonymous with improved health and recovery. Beyond antimicrobial efficacy, parameters such as morbidity and mortality related to lung function, cardiovascular health, and cancer should be prioritized. This narrative review emphasizes the critical need to emphasize clinical outcomes as much, if not more, than microbiological endpoints. We examine the underlying pathophysiological mechanisms and determinants of non-microbiological outcomes in tuberculosis, providing a synthesis of current knowledge. While there is growing evidence for some biomarkers to risk stratify TB patients for risk of all-cause mortality, relapse, or lung damage, no evidence was found on TB-associated cancer or cardiovascular disease. In addition to monitoring microbiologic outcomes, clinical trials and treatment cohorts need to capture patient-centered health dimensions more broadly. Finally, we highlight key research gaps and opportunities to evaluate non-microbiological biomarkers, aiming to improve patient monitoring and enable stratified approaches to tuberculosis management.

结核病药物试验的主要目的是确定具有最强杀伤结核分枝杆菌效力的抗生素方案。然而,微生物疗法并不是改善健康和康复的同义词。除抗菌效果外,应优先考虑与肺功能、心血管健康和癌症相关的发病率和死亡率等参数。这篇叙述性综述强调了强调临床结果的迫切需要,即使不是更多,也要比微生物终点强调得更多。我们研究了结核病的潜在病理生理机制和非微生物预后的决定因素,提供了当前知识的综合。虽然越来越多的证据表明,一些生物标志物可以根据全因死亡、复发或肺损伤的风险对结核病患者进行风险分层,但没有发现与结核病相关的癌症或心血管疾病相关的证据。除了监测微生物结果外,临床试验和治疗队列还需要更广泛地捕捉以患者为中心的健康维度。最后,我们强调了评估非微生物生物标志物的关键研究差距和机会,旨在改善患者监测并实现分层结核病管理方法。
{"title":"Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials.","authors":"Andrew R DiNardo, Wilbert Sabiiti, Stephen H Gillespie, Sophia B Georghiou, Norbert Heinrich, Norbert Hittel, Sami Taghlabi, Danna Carrero Longlax, Mikashmi Kohli, Ursula Panzner, Collins Musia, Christoph Lange, Anca Vasiliu, Rob J W Arts, Anna M Mandalakas, Morten Ruhwald, Lieven J Stuyver, Reinout van Crevel","doi":"10.3389/frabi.2025.1570989","DOIUrl":"10.3389/frabi.2025.1570989","url":null,"abstract":"<p><p>Tuberculosis drug trials are primarily designed to identify antibiotic regimens with the strongest potency to kill <i>Mycobacterium tuberculosis</i>. However, microbiologic cure is not synonymous with improved health and recovery. Beyond antimicrobial efficacy, parameters such as morbidity and mortality related to lung function, cardiovascular health, and cancer should be prioritized. This narrative review emphasizes the critical need to emphasize clinical outcomes as much, if not more, than microbiological endpoints. We examine the underlying pathophysiological mechanisms and determinants of non-microbiological outcomes in tuberculosis, providing a synthesis of current knowledge. While there is growing evidence for some biomarkers to risk stratify TB patients for risk of all-cause mortality, relapse, or lung damage, no evidence was found on TB-associated cancer or cardiovascular disease. In addition to monitoring microbiologic outcomes, clinical trials and treatment cohorts need to capture patient-centered health dimensions more broadly. Finally, we highlight key research gaps and opportunities to evaluate non-microbiological biomarkers, aiming to improve patient monitoring and enable stratified approaches to tuberculosis management.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1570989"},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144236026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in antibiotics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1